Dimethyl trisulfide (DMTS) is a natural organic trisulfide that has been patented as a promising antidotal candidate against cyanide (CN). The primary mode of action of DMTS is as a sulfur donor that enables the conversion of CN to thiocyanate. Recently, it was discovered that DMTS is capable of oxidizing hemoglobin (Hb) to methemoglobin (MetHb) in vitro. The goal of these experiments was to measure the extent of DMTS-induced MetHb formation in vivo. In these experiments, intramuscular (IM) injections of formulated DMTS were administered to mice. Following the IM injection, blood was drawn and analyzed for MetHb using a rapid spectrophotometric method. Methemoglobin levels peaked in a dose-dependent manner between 20 and 30 min., and then began dropping. The highest MetHb levels measured for the 50, 100, 200 and 250 mg/kg doses of DMTS were respectively 3.28, 6.12, 9.69, and 10.76% MetHb. These experiments provide the first experimental evidence that IM administered DMTS generates MetHb in vivo and provide additional evidence for the presence of a secondary therapeutic pathway for DMTS - CN scavenging by DMTS-generated MetHb.

中文翻译：

---

二甲基三硫化物在小鼠中形成高铁血红蛋白的作用。

二甲基三硫化物（DMTS）是一种天然有机三硫化物，已获得专利，有望成为针对氰化物（CN）的有希望的解毒剂。DMTS的主要作用方式是作为硫供体，使CN转化为硫氰酸酯。最近，发现DMTS能够在体外将血红蛋白（Hb）氧化为高铁血红蛋白（MetHb）。这些实验的目的是测量体内DMTS诱导的MetHb形成的程度。在这些实验中，对小鼠进行了肌肉内（IM）配制的DMTS注射。IM注射后，抽血并使用快速分光光度法分析MetHb。高铁血红蛋白水平在20至30分钟之间以剂量依赖性方式达到峰值，然后开始下降。在50、100，200和250 mg / kg的DMTS剂量分别为3.28、6.12、9.69和10.76％的MetHb。这些实验提供了IM施用DMTS体内产生MetHb的第一个实验证据，并提供了DMTS-CN通过DMTS产生的MetHb清除二级治疗途径的其他证据。